Toxicology News and Research

Latest Toxicology News and Research

New discovery in glioma-associated metabolic changes

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome", in The Proceedings of the National Academy of Sciences.

3 Mar 2011

Research: Tanning bed exposure can lead to serious skin problems

Tanning bed exposure can produce more than some tanners may bargain for, especially when they self-diagnose and use the radiation to treat skin eruptions, according to research conducted by the Indiana University School of Medicine Department of Dermatology.

2 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

Scientists discover lead contamination in ceramic cookware sold in Philadelphia's Chinatown

Recently, a research team from the Department of Emergency Medicine at Jefferson Medical College of Thomas Jefferson University discovered an alarming amount of lead contamination in ceramic cooking and eating utensils sold in Philadelphia's Chinatown.

1 Mar 2011

Excella achieves SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that Excella GmbH in Feucht, Germany has met the criteria established under the SafeBridge program for "Potent Compound Safety Certification" and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients ("APIs") and potent drug products.

1 Mar 2011

Preclinical data of Zalicus sodium channel compound published in journal PAIN

Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.

25 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

Toxic contamination of groundwater: South Australia residents warned

Australia’s Environment Protection Authority (EPA) has announced fears of groundwater contamination beneath up to 2000 homes. The EPA said that industrial activity at the former Hills Industries site in Edwardstown, south of Adelaide, caused dangerous materials - including a chemical known to cause cancer - to seep into the groundwater.

23 Feb 2011

Study shows chemical workers perceive high risk of safety threats

In an analysis of focus group interviews published in a scientific journal this month, a team of scientists found chemical workers perceive a high risk of on-the-job chemical threats, but are resigned to accepting the risks. The study also noted a certain level of distrust of management and health advisors, problems with written safety guides, and the need to include more experienced workers in the development of safety training programs.

23 Feb 2011

Study: Cannabis use may negatively impact male sexual performance

Rany Shamloul's recent review of the medical literature on cannabis use and sexual health has revealed that cannabis use may negatively impact male sexual performance.

23 Feb 2011

CompanDX, CRL enter multi-year agreement to develop biomarker panels

CompanDX Ltd., bioinformatics partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL), provider of laboratory testing services in molecular diagnostics and clinical trials, today announced they entered into a multi-year agreement to collaborate in the development and support of biomarker panels and companion diagnostic development for pharmaceutical, biotech and academic clients worldwide.

19 Feb 2011

European Commission bans fragrance material Musk xylene, in line with global IFRA Standards

The European Commission has just announced its decision to ban the fragrance material Musk xylene under the new European Chemicals Legislation REACH, bringing EU regulations in line with the global IFRA Standards.

19 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences, a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of a new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products.

17 Feb 2011

Ban called for allegedly carcinogenic caramel component in sodas

A consumer advocacy group has urged the U.S. Food and Drug Administration (FDA) this Wednesday to ban some chemically enhanced caramel food colorings used in widely consumed cola drinks as they could cause cancer.

16 Feb 2011

AMT 2010 total net income increases to EUR 1.4 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010.

16 Feb 2011

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Aeolus Pharmaceuticals, a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome.

16 Feb 2011

Scientists discover KCNH2 gene mutation in patients with long QT syndrome

Researchers from the Hospital Virgen de las Nieves of the University of Granada have identified the most frequent mutations in the gene KCNH2 in patients with long QT syndrome.

10 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011